General MedicationsRECTALGeneric
CANASA
MESALAMINE
Standard Dose
500MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview CANASA is listed in Drugs@FDA under application 021252 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient MESALAMINE Form and strength SUPPOSITORY;RECTAL - 500MG Sponsor ABBVIE Submission history Latest submission status date: 2023-10-24 00:00:00.
Structured Monograph
Clinical summary
Approval overview CANASA is listed in Drugs@FDA under application 021252 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient MESALAMINE Form and strength SUPPOSITORY;RECTAL - 500MG Sponsor ABBVIE Submission history Latest submission status date: 2023-10-24 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.